Tumour necrosis factor and inflammatory bowel disease

British Journal of Surgery

Volumn 84, Issue 8, 1997, Pages 1051-1058

  Armstrong, A M ^a   Gardiner, K R ^a   Kirk, S J ^a   Halliday, M I ^a   Rowlands, B J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; LACTULOSE; METALLOPROTEINASE; MONOCLONAL ANTIBODY CA2; MONOCLONAL ANTIBODY CDP 571; PENTOXIFYLLINE; SALAZOSULFAPYRIDINE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

CLINICAL TRIAL; COLITIS; CROHN DISEASE; ENTERITIS; HUMAN; IMMUNOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; STEROID THERAPY;

ANTIBODIES; HUMANS; INFLAMMATORY BOWEL DISEASES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0030749419     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840805     Document Type: Review

References (89)

1. MacDermott RP, Nash GS, Bertovitch MJ, Seiden MV, Bragdon MJ, Beale MG. Alterations of IgM, IgG, and IgA synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and Crohn's disease. Gastroenterology 1981; 81: 844-52.
2. Pullman WE, Elsbury S, Kobayashi M, Hapel AJ, Doe WF. Enhanced mucosal cytokine production in inflammatory bowel disease. Gastroenterology 1992; 102: 529-37.
3. Nakamura M, Saito H, Kasanuri J, Tamura Y, Yoshida S. Cytokine production in patients with inflammatory bowel disease. Gut 1992; 33: 933-7.
4. Stevens C, Walz G, Singaram C et al. Tumour necrosis factor α, interleukin-1β and interleukin-6 expression in inflammatory bowel disease. Dig Dis Sci 1992; 37: 818-26.
5. Nicholls S, Stephens S, Braegger CP, Walker-Smith JA, MacDonald TT. Cytokines in stools of children with inflammatory bowel disease or infective diarrhoea. J Clin Pathol 1993; 46: 757-60.
6. Kucharzik T, Stoll R, Lugering N, Domschke W. Circulating antiinflammatory cytokine IL-10 in patients with inflammatory bowel disease. Clin Exp Immunol 1995; 100: 452-6.
7. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor and interleukin-6 by human monocytes. Infect Immun 1994; 62: 2715-21.
8. Keller R, Gehri R, Keist R. Macrophage responses to viruses, protozoa and fungi: secretory and cellular activities in resting unprimed bone marrow-derived mononuclear phagocytes. Cell Immunol 1994; 159: 323-30.
9. Beutler B, Tkacenko V, Milsark I, Krochin N, Cerami A. Effect of gamma interferon on cachectin expression by mononuclear phagocytes. Reversal of the Ipsd (endotoxin resistance) phenotype. J Exp Med 1986; 164: 1791-6.
10. Dembic Z, Loetscher H, Gubler U et al. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences. Cytokine 1990; 2: 231-7.
11. Rothe J, Gehr G, Loetscher H, Lessauer W. Tumour necrosis factor receptors, structure and function. Immunol Res 1992; 11: 81-90.
12. Aderka D, Engelmann H, Maor Y, Brakebusch X, Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992; 175: 323-9.
13. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264: 1974-80.
14. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Annu Rev Med 1994; 45: 491-503.
15. Foley N, Lambert C, McNicol M, Johnson N, Rook GA. An inhibitor of the toxicity of tumour necrosis factor in the serum of patients with sarcoidosis, tuberculosis and Crohn's disease. Clin Exp Immunol 1990; 80: 395-9.
16. Tracey KJ, Cerami A. Tumor necrosis factor in the malnutrition (cachexia) of infection and cancer. Am J Trop Med Hyg 1992; 47(Suppl): 2-7.
17. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986; 320: 584-8.
18. Sun XM, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988; 81: 1328-31.
19. Eliakim R, Karmeli F, Razin E, Rachmliewitz D. Role of platelet-activating factor in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine and prednisolone. Gastroenterology 1988; 95: 1167-72.
20. Bienvenu J, Coulon L, Doche C, Gutowski M-C, Grau GE. Analytical performances of commercial ELISA-kits for IL-2, IL-6 and TNFα. A WHO study. Eur Cytokine Netw 1993; 4: 447-51.
21. Kreuzer KA, Rockstroh JK, Sauerbruch T, Spengler U. A comparative study of different enzyme immunosorbent assays for human tumor necrosis factor-alpha. J Immunol Methods 1996; 195: 49-54.
22. James K. Interactions between cytokines and α2-macroglobulin. Immunol Today 1990; 11: 163-6.
23. Engelberts I, Stephens S, Francot GJ, van der Linden CJ, Buurman WA. Evidence for different effects of soluble TNF-receptors on various TNF measurements in human biological fluids. Lancet 1991; 338: 515-16.
24. Neilly PJD, Campbell GR, Anderson NM, Gardiner KR, Kirk SJ, Rowlands BJ. Faecal and systemic tumour necrosis factor in experimental inflammatory bowel disease. Surgical Research Communications 1995; 18: 11-17.
25. Neilly PJ, Gardiner KR, Kirk SJ et al. Endotoxaemia and cytokine production in experimental colitis. Br J Surg 1995; 82: 1479-82.
26. Mack DR, Lau AS, Sherman PM. Systemic tumour necrosis factor production in experimental colitis. Dig Dis Sci 1992; 37: 1738-45.
27. Watkins PE, Foulkes R, Stephens S, Ward P, Warren BF. Faecal tumour necrosis factor alpha in cotton top tamarin colitis. J Pathol 1993; 170(Suppl 1): A364 (Abstract).
28. Harendra de Silva DG, Mendis LN, Sheron N et al. Concentrations of interteukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. Gut 1993; 34: 194-8.
29. Braeger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor α in stool as a marker of intestinal inflammation. Lancet 1992; 339: 89-91.
30. Casellas F, Papo M, Guarner F, Antolin M, Armengol JR, Malagelada JR. Intraluminal colonic release of immunoreactive tumour necrosis factor in chronic ulcerative colitis. Clin Sci 1994; 87: 453-8.
31. Murch SH, Lamkin VA, Savage MO, Walker-Smith JA, MacDonald TT. Serum concentrations of tumour necrosis factor in childhood inflammatory bowel disease. Gut 1991; 32: 913-17.
32. Hyams JS, Treem WR, Eddy E, Wyzga N, Moore RE. Tumour necrosis factor-alpha is not elevated in children with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1991; 12: 233-6.
33. Nielsen OH, Brynskov J, Bendtzen K. Circulating and mucosal concentrations of tumour necrosis factor and inhibitor(s) in inflammatory bowel disease. Dan Med Bull 1993; 40: 247-9.
34. Gardiner KR, Halliday MI, Barclay GR et al. Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995; 36: 897-901.
35. Sategna-Guidetti X, Pulitano R, Fenoglio L, Bologna E, Manes M, Camussi G. Tumor necrosis factor/cachectin in Crohn's disease. Relation of serum concentration to disease activity. Recenti Prog Med 1993; 84: 93-9.
36. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin-6 production in Crohn's disease. Gastroenterology 1992; 102: 514-19.
37. Mahida YR, Kurlac L, Gallagher A, Hawkey CJ. High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis. Gut 1991; 32: 1531-4.
38. Weil D. What's new about tumor necrosis factor? Report on the fourth TNF International Congress. Eur Cytokine Netw 1992; 3: 347-51.
39. Murch SH, Braegger CP, Walker-Smith JA, MacDonald TT. Location of tumour necrosis factor by immunohistochemistry in chronic inflammatory bowel disease. Gut 1993; 34: 1705-9.
40. Olson AD, Ayass M, Chensue S. Tumor necrosis factor and IL-1β expression in pediatric patients with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 1993; 16: 241-6.
41. Breese EJ, Michie CA, Nicholls SW et al. Tumour necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994; 106: 1455-66.
42. Beil WJ, Weller PF, Peppercorn MA, Galli SJ, Dvorak AM. Ultrastructural immunogold localization of subcellular sites of TNFα in colonic Crohn's disease. J Leukoc Biol 1995; 58: 284-98.
43. Reinecker HC, Steffen M, Withoeft T et al. Enhanced secretion of tumour necrosis factor, IL-6, and IL-1β by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 1993; 94: 174-81.
44. Bouma G, Oudkerk P, Scharenberg JG et al. Differences in the intrinsic capacity of peripheral blood mononuclear cells to produce tumor necrosis factor alpha and beta in patients with inflammatory bowel disease and healthy controls. Scand J Gastroenterol 1995; 30: 1095-100.
45. Mazlam MZ, Hodgson HJ. Peripheral blood monocyte cytokine production and acute phase response in inflammatory bowel disease. Gut 1992; 33: 773-8.
46. Isaacs KL, Sartor RB, Haskill S. Cytokine messenger RNA profiles in inflammatory bowel disease detected by polymerase chain reaction amplification. Gastroenterology 1992; 103: 1587-95.
47. Stronkhorst A, Jansen J, Tytgat GNJ, van Deventer SJH. Soluble IL2 and TNF receptor p55 and p75 in Crohn's disease. Gastroenterology 1994; 104: 779A.
48. Hudson M, Gallati H, Ryff JC, Pounder RE, Wakefield AJ. Serum tumour necrosis factor (TNF) and soluble TNF receptors p55 and p75 in Crohn's disease. Gastroenterology 1993; 104(Suppl): A715 (Abstract).
49. Aderka D, Engelmann H, Shemer-Avni Y et al. Variation in serum levels of soluble TNF receptors among healthy adults. Lymphokine Cytokine Res 1992; 11: 157-9.
50. Hadsiselimovic F, Emmons LR, Gallati H. Soluble tumour necrosis factor receptors p55 and p75 in the urine monitor disease activity and the efficacy of treatment of inflammatory bowel disease. Gut 1995; 37: 260-3.
51. Prantera C, Davioli M, Lorenzetti R et al. Clinical and laboratory indicators of the extent of ulcerative colitis. Serum C-reactive protein helps the most. J Clin Gastroenterol 1988; 10: 41-5.
52. Fomsgaard A, Svenson M, Bendtzen K. Auto-antibodies to tumour necrosis factor in healthy humans and patients with inflammatory diseases and Gram-negative bacterial infections. Scand J Immunol 1989; 30: 219-23.
53. Beutler B, Krochin N, Milsark IW, Luedke C, Cerami A. Control of cachectin (tumor necrosis factor) synthesis: mechanisms of endotoxin resistance. Science 1986; 232: 977-80.
54. Shanahan F, Niederlehner A, Carramanzana N, Anton P. Sulphasalazine inhibits the binding of TNF-α to its receptor. Immunopharmacology 1990; 20: 217-24.
55. Travis SP, Jewell DP. Salicylates for ulcerative colitis - their mode of action. Pharmacol Ther 1994; 63: 135-61.
56. Greve JW, Gouma DJ, von Leeuwen PAM, Buurman WA. Lactulose inhibits endotoxin induced tumour necrosis factor production by monocytes. An in vitro study. Gut 1990; 31: 198-203.
57. Bemelmans MHA, Gouma DJ, Greve JW, Buurman WA. Effect of antitumour necrosis factor treatment on circulating tumour necrosis factor levels and mortality after surgery in jaundiced mice. Br J Surg 1993; 80: 1055-8.
58. Gardiner KR, Erwin PJ, Anderson NH, McCaigue MD, Halliday MI, Rowlands BJ. Lactulose as an antiendotoxin in experimental colitis. Br J Surg 1995; 82: 469-72.
59. Liao W, Cui X-S, Jin X-Y, Floren C-H. Lactulose: a potential drug for the treatment of inflammatory bowel disease. Med Hypotheses 1994; 43: 234-8.
60. Refsum SE, McCaigue M, Campbell GR et al. Pentoxifylline modulates cytokine responses in a sepsis model. Prog Clin Biol Res 1994; 388: 323-33.
61. Bauditz J, Ruckert Y, Raedler A, Nikolaus S, Lochs H, Schreiber S. Tumour necrosis factor inhibition by oxpentifylline and intestinal inflammation in Crohn's disease. Lancet 1995; 345: 1445 (Letter).
62. Bauditz J, Haemling J, Nikolaus S et al. Treatment of steroid dependent Crohn's disease with pentoxifylline (PTX). Gastroenterology 1996; 110: A861 (Abstract).
63. Bucala R, Ritchlin C, Winchester R, Cerami A. Constitutive production of inflammatory and mitogenic cytokines by rheumatoid synovial fibroblasts. J Exp Med 1991; 173: 569-74.
64. Neilly PJ, Gardiner KR, Kirk SJ et al. Anti-TNF-alpha antibody reduces the systemic inflammatory response in experimental colitis. Gut 1995; 37(Suppl 2): A16 (Abstract).
65. Videla S, Vilaseca G, Gonzalez A et al. Role of tumor necrosis factor in hapten-induced colitis. Gastroenterology 1966; 110: A1039 (Abstract).
66. Neurath MF, Kollias G, Duchmann R, Fuss I, Strober W, Meyer K-H. Effects of antibodies to TNFα on acute and chronic experimental colitis in mice. Gastroenterology 1996; 110: A979 (Abstract).
67. Watkins PE, Foulkes R, Stephens S, Ward P, Warren BF. Treatment of inflammatory bowel disease using anti-tumour necrosis factor 2 antibody. Br J Surg 1995; 82: 693-4 (Abstract).
68. Derkx B, Taminiau J, Radema S et al. Tumour-necrosis-factor antibody treatment in Crohn's disease. Lancet 1993; 342: 173-4 (Letter).
69. Baert F, D'Haens G, Geboes K, Ectors N, Rutgeerts P. TNF-alpha antibody therapy causes a fast and dramatic decrease of histological colonic inflammation in Crohn's disease but not ulcerative colitis. Gastroenterology 1996; 110: A859 (Abstract).
70. Evans RC, Clark L, Heath P, Rhodes JM. Treatment of ulcerative colitis with an engineered human anti-TNF-alpha antibody CDP571. Gastroenterology 1996; 110: A905 (Abstract).
71. Sands BE, Podolsky DK, Tremaine WJ et al. Chimeric monoclonal anti-tumor necrosis factor antibody (cA2) in the treatment of severe, steroid-refractory ulcerative colitis (UC). Gastroenterology 1996; 110: A1008 (Abstract).
72. Van Dullemen HM, van Deventer SJH, Hommes DW et al. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 1995; 109: 129-35.
73. McCabe RP, Woody J, van Deventer S et al. A multicenter trial of cA2 anti-TNF chimeric monoclonal antibody in patients with active Crohn's disease. Gastroenterology 1996; 110: A962 (Abstract).
74. Stack W, Mann S, Roy A et al. The effects of CDP571, an engineered human IgG4 anti-TNF-alpha antibody in Crohn's disease. Gut 1996; 38(Suppl 1): A27 (Abstract).
75. Stack WA, Mann SD, Roy AJ et al. Randomised controlled trial of CDP571 antibodv to tumour necrosis factor α in Crohn's disease. Lancet 1997; 349: 521-4.
76. Baert F, Peeters M, D'Haens G, Geboes K, Ectors N, Rutgeerts P. Impressive histologic improvement after TNF antibody (cA2) therapy in active Crohn's disease. Gut 1996; 39(Suppl 1): A17 (Abstract).
77. Targan SR, Rutgeerts P, Hanauer SB et al. A multicentre trial of anti-tumor necrosis factor (TNF) antibody (cA2) treatment of patients with active Crohn's disease. Gastroenterology 1996; 110: A1026 (Abstract).
78. Plevy SE, Carramanzana NM, Deem RL, Woody WJ, Targan SR. Clinical improvement in Crohn's disease (CD) patients treated with anti-TNF-alpha correlates with downregulated mueosal T helper 1 responses. Gastroenterology 1996; 110: A993 (Abstract).
79. Suitters AJ, Foulkes R, Opal SM et al. Differential effect of isotype on efficacy of anti-tumor necrosis factor chimeric antibodies in experimental septic shock. J Exp Med 1994; 179: 849-56.
80. Scallon BJ, Moore MA, Trinh H, Knight DM, Ghrayeb J. Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions. Cytokine 1995; 7: 251-9.
81. Levine DS, Fischer SH, Christie DL, Haggitt RC, Ochs HD. Intravenous immunoglobulin therapy for active, extensive, and medically refractory idiopathic ulcerative or Crohn's colitis. Am J Gastroenterol 1992; 87: 91-100.
82. Feldmann M, Brennan FM, Elliott M, Katsikis P, Maini RN. TNFα as a target in rheumatoid arthritis. Circ Shock 1994; 43: 179-84.
83. Elliott MJ, Maini RN, Feldmann M et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet 1994; 344: 1105-10.
84. Elliott MJ, Maini RN, Feldmann M et al. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet 1994; 344: 1125-7.
85. Gearing AJ, Beckett P, Christodoulou M et al. Processing of tumour necrosis factor-alpha precursor by metalloproteinases. Nature 1994; 370: 555-7.
86. McGeehan GM, Becherer JD, Bast RC Jr et al. Regulation of tumour necrosis factor-alpha processing by a metalloproteinase inhibitor. Nature 1994; 370: 558-61.
87. Mohler KM, Sleath PR, Fitzner JN et al. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing. Nature 1994; 370: 218-20.
88. Espat NJ, Cendan JC, Beirle EA et al. PEG-BP-30 monotherapy attenuates the cytokine-mediated inflammatory cascade in baboon Escherichia coli septic shock. J Surg Res 1995; 59: 153-8.
89. Peppel K, Crawford D, Beutler B. A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity. J Exp Med 1991; 174: 1483-9.